deltatrials
Completed PHASE1 NCT00689507

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Applied Molecular Evolution

Conditions Multiple Myeloma
Interventions LY2127399
Updated 6 times since 2017 Last updated: Jun 25, 2015 Started: Mar 31, 2008 Primary completion: Jan 31, 2013 Completion: May 31, 2014

Listed as NCT00689507, this PHASE1 trial focuses on Multiple Myeloma and remains completed. Sponsored by Applied Molecular Evolution, it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Applied Molecular Evolution
  • Eli Lilly and Company
Data source: Applied Molecular Evolution

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Birmingham, United States
  • • Boston, United States
  • • Iowa City, United States
  • • Los Angeles, United States
  • • Omaha, United States
  • • Philadelphia, United States